{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.9","value":"2.59"}]}],"title":"C1D1 (n= 593)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.0","value":"83.2"}]}],"title":"C2D1 (n= 534)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.8","value":"130"}]}],"title":"C3D1 (n= 445)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66.4","value":"158"}]}],"title":"C4D1 (n= 405)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.4","value":"205"}]}],"title":"C8D1 (n= 222)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"105","value":"226"}]}],"title":"C16D1 (n= 132)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.8","value":"250"}]}],"title":"C24D1 (n= 63)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"117","value":"277"}]}],"title":"C32D1 (n= 11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"101","value":"144"}]}],"title":"EOT (n= 347)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"10.4"}]}],"title":"120 days after EOT (n= 124)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"606"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Atezolizumab"}],"paramType":"MEAN","populationDescription":"PK evaluable participants. Here, 'n' signifies those participants evaluated for this measure at specific time point. All 606 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.","reportingStatus":"POSTED","timeFrame":"Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days)","title":"Minimum Observed Serum Atezolizumab Concentration (Cmin)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}